HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma-Reference-Cited by-同舟云学术

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Published:2016-03-10 Issue:16 Volume:22 Page:4119-4132
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Zheng Hong,Zhao Weipeng,Yan Cihui,Watson Crystina C.,Massengill Michael,Xie Mengyu,Massengill Chris,Noyes David R.,Martinez Gary V.,Afzal Roha,Chen Zhihua,Ren Xiubao,Antonia Scott J.,Haura Eric B.,Ruffell Brian,Beg Amer A.

Funder

Lung Cancer

Moffitt Cancer CenterNational Natural Science Foundation of ChinaNational Natural Science Foundation of China

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 277 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer;ESMO Real World Data and Digital Oncology;2024-09

2. Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies;Critical Reviews in Oncology/Hematology;2024-09

3. Cracking the Codes behind Cancer Cells’ Immune Evasion;International Journal of Molecular Sciences;2024-08-15

4. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

5. DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma;OncoImmunology;2024-08-05